Literature DB >> 18940579

Economic assessment of different modalities of immunoglobulin replacement therapy.

Stephen K Membe1, Chuong Ho, Karen Cimon, Andra Morrison, Amin Kanani, Chaim M Roifman.   

Abstract

The delivery (intravenous or subcutaneous), location (home or hospital), and other factors of immunoglobulin replacement therapy are examined for cost effectiveness. Cost-minimization studies from several countries are reviewed and analyzed. A Canadian cost-minimization study is performed. Although common themes emerge, there are cost differences between the various countries.

Mesh：

Year:  2008        PMID： 18940579     DOI： 10.1016/j.iac.2008.06.008

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  10 in total

Review 1.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

2.  Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

Authors:  Di Sun; Jennifer R Heimall; Matthew J Greenhawt; Nancy J Bunin; Marcus S Shaker; Neil Romberg
Journal:  JAMA Pediatr       Date:  2022-02-01       Impact factor: 16.193

3.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

4.  Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Authors:  J Beauté; P Levy; V Millet; M Debré; Y Dudoit; L Le Mignot; A Tajahmady; C Thomas; F Suarez; I Pellier; O Hermine; N Aladjidi; N Mahlaoui; A Fischer
Journal:  Clin Exp Immunol       Date:  2009-12-16       Impact factor: 4.330

5.  Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-01

6.  Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Authors:  A Martin; L Lavoie; M Goetghebeur; R Schellenberg
Journal:  Transfus Med       Date:  2012-11-20       Impact factor: 2.057

7.  Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy.

Authors:  Julia Zhu; Heather S Kirkham; Gretchen Ayer; Chi-Chang Chen; Rolin L Wade; Swapna U Karkare; Chester H Robson; Jordan S Orange
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-19

8.  Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.

Authors:  Hosein Shabaninejad; Asra Asgharzadeh; Aziz Rezapour; Nima Rezaei
Journal:  Med J Islam Repub Iran       Date:  2017-12-17

9.  Outcome Evaluation of a Subcutaneous Immunoglobulin Clinical Management Program.

Authors:  Julia Zhu; Gretchen Ayer; Heather S Kirkham; Chi-Chang Chen; Rolin L Wade; Swapna U Karkare; Chester H Robson; Jordan S Orange
Journal:  J Res Pharm Pract       Date:  2019 Apr-Jun

10.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.